
Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

HOOKIPA bags US$10m cancer milestone
The Vienna-based arenavirus specialist got the non-dilutive milestone payment for advancing its drug programme HB-700, a novel arenaviral...

5 Alarm Bio Ltd raises £500K in seed round
Cambridge Angels, Meltwind, o2h Ventures, SyndicateRoom, as well as other angel investors participated in Five Alarm Bio’s (FAB) seed round with...

Confo Therapeutics and Lilly partner to advance CFTX-1554
Under the agreement, Confo Therapeutics BV got a $40m upfront and milestone payments totalling $590m for licencing its clinical stage angiotensin II...

Upscaling AAV gene therapy
Mid-March marks the start of the collaboration of Remedium Bio Inc. and Biovial Oy on an AAV gene therapy for osteoarthritis. Rheumatology and...

German HTGF IV fund closes at €493m
Alongside the Federal Ministry of Economics and Climate Protection (BMWK) and KfW Capital, 45 private investors (companies) participated in HTGF IV...

Free sugar linked to higher cardiovascular disease
The findings of a group headed by Rebecca Kelly at University Oxford (doi: 10.1186/s12916-022-02712-7) strengthen the evidence for the global...